Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Stem Cell Research

Executive Summary: Y-27632 dihydrochloride is a potent and selective inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, with IC50 values of 140 nM and a Ki of 300 nM, respectively (APExBIO). This compound demonstrates >200-fold selectivity over other kinases, such as PKC and MLCK, under defined in vitro conditions. Y-27632 is widely used in stem cell cultures to enhance viability and promote expansion. It disrupts Rho-mediated stress fiber formation, modulates cell cycle progression, and suppresses tumor invasion in vivo (Ni et al., 2022). The compound exhibits high solubility in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), and water (≥52.9 mg/mL), facilitating diverse laboratory workflows.

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases that regulate the actin cytoskeleton, cell adhesion, and migration. The Rho/ROCK signaling pathway orchestrates cytoskeletal dynamics, mediates cell contractility, and is essential for processes such as cytokinesis, cell proliferation, and apoptosis. Dysregulation of ROCK activity is implicated in cancer progression, neurodegeneration, and fibrotic diseases (Ni et al., 2022). Selective inhibition of ROCK kinases allows precise dissection of these pathways in both normal and pathological contexts.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride binds competitively to the ATP-binding site of ROCK1 and ROCK2 catalytic domains. Its IC50 for ROCK1 is approximately 140 nM, and the Ki for ROCK2 is 300 nM, indicating high potency under standard assay conditions (pH 7.4, 25°C) (APExBIO). The compound displays over 200-fold selectivity against kinases such as protein kinase C (PKC), cAMP-dependent protein kinase (PKA), myosin light chain kinase (MLCK), and p21-activated kinase (PAK). Inhibition of ROCK prevents RhoA-induced phosphorylation of downstream effectors, disrupts actin-myosin contractility, and abolishes the formation of actin stress fibers. Y-27632 also modulates cell cycle progression from G1 to S phase and impairs cytokinesis, resulting in altered cell division dynamics. These molecular effects collectively support applications in cell proliferation, cytoskeletal reorganization, and inhibition of tumor cell invasion (see also: Y-27632 Dihydrochloride: Advanced ROCK Inhibition for Cell Science; this article extends protocol detail and mechanistic clarity for translational studies).

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC50 of 140 nM and ROCK2 with a Ki of 300 nM in cell-free kinase assays (APExBIO).
• Displays >200-fold selectivity versus PKC, PKA, MLCK, and PAK in parallel kinase panels (APExBIO technical sheet).
• Enhances survival and proliferation of human induced pluripotent stem cells (iPSCs) by reducing apoptosis post-dissociation (Ni et al., 2022, DOI).
• Reduces proliferation of prostatic smooth muscle cells in vitro in a concentration-dependent manner (APExBIO).
• Suppresses tumor invasion and metastasis in mouse xenograft models by modulating cytoskeletal architecture (Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal Dynamics; this review complements our focus by summarizing anti-invasive strategies).
• Highly soluble in DMSO, ethanol, and water, supporting broad experimental integration (APExBIO technical data).
• Does not induce pluripotency but preserves viability and pluripotency marker expression during iPSC culture (Ni et al., 2022, DOI).

Applications, Limits & Misconceptions

Core Applications

• Stem Cell Viability Enhancement: Prevents dissociation-induced apoptosis in human pluripotent stem cells; supports survival during colony passage (Ni et al., 2022).
• Cytoskeletal Research: Dissects Rho/ROCK signaling effects on actin fiber assembly and cell morphology.
• Oncology: Reduces tumor cell invasion and metastasis in preclinical models via suppression of ROCK-mediated cytoskeletal rearrangements (Dissecting Progenitor Cell Regulation with Y-27632; this article integrates morphogenesis insights, whereas our review provides broader translational context).
• Cell Proliferation Assays: Modulates cell cycle progression and cytokinesis for mechanistic studies.

Common Pitfalls or Misconceptions

• Y-27632 dihydrochloride does not induce pluripotency; it supports survival of existing pluripotent cells (Ni et al., 2022).
• It is not a pan-kinase inhibitor; activity is highly selective for ROCK1/2.
• Long-term solution storage (>several months) at -20°C is discouraged due to degradation risk (APExBIO).
• Off-target effects may occur at concentrations far above assay-recommended levels (>10 μM).
• Y-27632 does not reverse established cell differentiation; it is used to maintain undifferentiated, proliferative states.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid and should be stored desiccated at 4°C or below. For use, dissolve in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), or water (≥52.9 mg/mL). Solubility increases with warming to 37°C or via ultrasonic bath. Prepare aliquots for single-use to avoid repeated freeze-thaw cycles. Stock solutions are stable below -20°C for several months, but long-term solution storage is not advised. Typical working concentrations in cell culture range from 1–10 μM. In stem cell workflows, supplement medium immediately after cell dissociation to minimize apoptosis. For cancer invasion assays, titrate concentration to avoid cytotoxicity while ensuring ROCK pathway inhibition. For expanded troubleshooting and advanced workflows, see Y-27632 Dihydrochloride: Advanced ROCK Inhibition for Cell Science, which provides cross-study insights and troubleshooting strategies not covered in this overview.

Conclusion & Outlook

Y-27632 dihydrochloride is a gold-standard, cell-permeable ROCK inhibitor provided by APExBIO (A3008) for dissecting Rho/ROCK signaling in cytoskeletal, stem cell, and oncology research. Its high potency, selectivity, and robust solubility profile underpin its widespread adoption. As new regenerative and cancer models emerge, Y-27632 will remain a cornerstone compound for mechanistic studies and translational workflows. For current specifications, protocols, and ordering information, consult the Y-27632 dihydrochloride product page. For strategic guidance on cytoskeletal studies, see Y-27632 Dihydrochloride: Selective ROCK Inhibition for Cy..., which this article updates by integrating the latest data on stem cell and tumor biology.